The Global Need and Availability of Plasma Coagulation Factors VIII and IX in Hemophilia Context: A Global Health Estimate Reporting

Abstract

Background: Blood components supplying is essential for health systems worldwild. However, the availability, need and unmet need of plasma derived coagulation factors, fully intended for hemophilia treatment, are often unknown. Methods: We aimed to estimate availability, need and unmet need of plasma derived coagulation factors VIII and IX in national, regional and global level. Data from 2018 Report on the Annual Global Survey by The World Federation of Hemophilia was used to get plasmatic factors usage (considered equivalent to availability) of countries covering 87% to 88% of global scope. We used the 2017 European consensus for treatment of hemophilia on minimum consumption of factors VIII and IX 4 UI and 0·5UI per capita, considered equivalent to factor need. The unmet need was the difference between need and availability. Findings: Among the 111 countries reporting factor VIII use, remained a 84 country sample with 95% confidence interval and among 105 countries reporting factor IX use, remained a 77 country sample and same confidence interval. The availability was above need in four countries for factor VIII and in 11 countries for factor IX. Interpretation: Although not always was possible to identify trends related to socioeconomic aspect, great part of the sub-Saharan Africa and south Asia countries had elevated unmet needs for both plasmatic factors. In order to overcome the scarce information on this set, this study can potentially contribute to better organized and better planned health systems to benefit both individuals and whole populations. Funding: None Declaration of Interests: All other authors declare no competing interests. Ethics Approval Statement: The present study did not require approval by an institutional review board.